Drug survival, effectiveness and safety of guselkumab for moderate-to-severe psoriasis for up to 4 years
Clinical and Experimental Dermatology · 2025
DOI: 10.1093/ced/llaf010 ↗Kurz gefasst
Fachartikel in der Zeitschrift Clinical and Experimental Dermatology, 2025. Verfasst von Luca Mastorino und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical Sciences, Section of Dermatology, University of Turin, Turin, Italy. Hauptthemen laut MEDLINE: Psoriasis, Dermatologic Agents, Antibodies, Monoclonal. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 25 Literaturangaben.
Abstract (Originalsprache)
Background
Guselkumab has been shown to be safe and effective for the treatment of psoriasis in numerous randomized clinical trials and real-life studies. Real-life data on treatment up to 4 years are lacking.
Objectives
The present study aims to estimate the drug survival, effectiveness and safety of guselkumab over a period of 208 weeks.
Methods
We included all consecutive patients with psoriasis or psoriatic arthritis receiving at least one dose of guselkumab. Effectiveness was evaluated as achieving 100% or ≥ 90% improvement in the Psoriasis Area and Severity Index (PASI 100 or PASI 90) and absolute PASI ≤ 3. Drug survival was evaluated using the Kaplan–Meyer curves.
Results
In total, 202 patients were studied. Their mean PASI decreased from 10.9 (SD 5.76) at baseline to 0.48 at week 208. Rates of PASI 100 response improved over time: the outcome was achieved in 30.0% and 65% of patients at weeks 16 and 208, respectively. For PASI 90 and PASI ≤ 3 we found similar trends. After 208 weeks of treatment, the estimated rate of drug survival was 68.5% in observed cases. Being super responders (SRs) according to our definition (P = 0.005) and the GUIDE definition (P < 0.001) reduced the risk of drug interruption, as did cardiovascular comorbidities. In our population, none of the baseline characteristics showed a clear impact on the effectiveness of guselkumab. Considering both SR definitions, in our cohort, being an SR was associated with a better response in the long term when considering PASI 100 and 90 in both linear and multivariate analyses.
Conclusions
Our study confirms the good effectiveness and favourable safety profile of guselkumab in a real-world setting up to 4 years.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Medical Sciences, Section of Dermatology, University of Turin, Turin, Italy.
Zitieren
APA
Mastorino, L., Dapavo, P., Ortoncelli, M., Stroppiana, E., Verrone, A., Astrua, C., Fiasconaro, C., Liao, Y., Gallo, G., Quaglino, P., & Ribero, S. (2025). Drug survival, effectiveness and safety of guselkumab for moderate-to-severe psoriasis for up to 4 years. Clinical and Experimental Dermatology. https://doi.org/10.1093/ced/llaf010
Vancouver
Mastorino L, Dapavo P, Ortoncelli M, Stroppiana E, Verrone A, Astrua C, et al. Drug survival, effectiveness and safety of guselkumab for moderate-to-severe psoriasis for up to 4 years. Clinical and Experimental Dermatology. 2025. doi:10.1093/ced/llaf010
BibTeX
@article{Mastorino2025,
author = {Mastorino, Luca and Dapavo, Paolo and Ortoncelli, Michela and Stroppiana, Elena and Verrone, Anna and Astrua, Chiara and Fiasconaro, Chiara and Liao, Yingying and Gallo, Giuseppe and Quaglino, Pietro and Ribero, Simone},
title = {Drug survival, effectiveness and safety of guselkumab for moderate-to-severe psoriasis for up to 4 years},
journal = {Clinical and Experimental Dermatology},
year = {2025},
doi = {10.1093/ced/llaf010}
}
EUVIMED